Search for: [Abstract = "Central nervous system \(CNS\) disorders, such as dementia and Alzheimer's disease \(AD\), occupy a prominent place among civilization diseases. They are becoming a problem in our society, due to their ever\-increasing prevalence and because of the lack of access to effective treatment therapies. The neurodegenerative disease with a complex aetiology which is AD is the most widespread memory dysfunction, which particularly affects the elderly. In addition, no new synthetic drug effective in AD has appeared on the pharmaceutical market for more than two decades. To date, various protein targets that may be involved in AD therapy have been classified, including serotonin 5\-HT6 receptor \(5\-HT6R\) and cyclin\-dependent kinase 5 \(CDK5\). The aforementioned two protein targets have been selected as therapeutic targets in the research of this dissertation. The main aim of this research was the design, chemical synthesis and in vitro and in vivo evaluation of the pharmacological properties of new 5\-HT6R ligands, 1,3,5\-triazine derivatives, as well as computer\-aided SAR analysis of the obtained final compounds. Different chemical modifications were also planned to extend the pharmacological profile of the compounds to an additional AD\-related target selected from among the enzyme proteins, i.e. CDK5\/p25. In\-house studies planned also included in vitro ADMETox assays and structure\-activity rela"]

Number of results: 1